Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI

Abstract

Platelet inhibition remains the core pharmacotherapy component in patients undergoing emergency or primary percutaneous coronary interventions (PCI). This can be achieved using a number of intravenous and oral preparations. Intravenous (iv) antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the only available intravenous P(2)Y(12) inhibitor, cangrelor. Available oral agents include aspirin and various P(2)Y(12) inhibitors or their analogues. These are usually used in combination with the intention to maintain dual antiplatelet therapy (DAPT) for a period of time (generally up to 12 months) after the index PCI procedure.